Florence Schleich

Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma.

Is FENO50 useful diagnostic tool in suspected asthma?

Corticosteroids: still at the frontline in asthma treatment?

Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation.

Importance of concomitant local and systemic eosinophilia in uncontrolled asthma.

Importance of concomitant local and systemic eosinophilia in uncontrolled asthma.

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).

Biomarkers in the Management of Difficult Asthma.

Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD.

Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory?

Asthma inflammatory phenotypes show differential microRNA expression in sputum.

Lung-resident eosinophils represent a distinct regulatory eosinophil subset.

A historical perspective: Are inhaled corticoids sufficient to control asthma?

Asthma Control and Sputum Eosinophils: A Longitudinal Study in Daily Practice.

Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers?

Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.